Rigel Operating Income from 2010 to 2026
| RIGL Stock | USD 35.46 1.18 3.22% |
Operating Income | First Reported 2000-03-31 | Previous Quarter 61.1 M | Current Value 28.4 M | Quarterly Volatility 16.6 M |
Check Rigel Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Rigel Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.7 M, Interest Expense of 9.6 M or Total Revenue of 216.5 M, as well as many indicators such as Price To Sales Ratio of 1.8, Dividend Yield of 0.0 or PTB Ratio of 109. Rigel financial statements analysis is a perfect complement when working with Rigel Pharmaceuticals Valuation or Volatility modules.
Rigel | Operating Income | Build AI portfolio with Rigel Stock |
Historical Operating Income data for Rigel Pharmaceuticals serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Rigel Pharmaceuticals represents a compelling investment opportunity.
Latest Rigel Pharmaceuticals' Operating Income Growth Pattern
Below is the plot of the Operating Income of Rigel Pharmaceuticals over the last few years. Operating Income is the amount of profit realized from Rigel Pharmaceuticals operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Rigel Pharmaceuticals is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Rigel Pharmaceuticals' Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Rigel Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Operating Income | 10 Years Trend |
|
Operating Income |
| Timeline |
Rigel Operating Income Regression Statistics
| Arithmetic Mean | (44,570,727) | |
| Geometric Mean | 44,339,316 | |
| Coefficient Of Variation | (98.26) | |
| Mean Deviation | 37,550,556 | |
| Median | (55,550,000) | |
| Standard Deviation | 43,797,096 | |
| Sample Variance | 1918.2T | |
| Range | 128.6M | |
| R-Value | 0.73 | |
| Mean Square Error | 968T | |
| R-Squared | 0.53 | |
| Significance | 0.001 | |
| Slope | 6,295,486 | |
| Total Sum of Squares | 30691T |
Rigel Operating Income History
Other Fundumenentals of Rigel Pharmaceuticals
Rigel Pharmaceuticals Operating Income component correlations
Click cells to compare fundamentals
About Rigel Pharmaceuticals Financial Statements
Rigel Pharmaceuticals investors utilize fundamental indicators, such as Operating Income, to predict how Rigel Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Operating Income | 27.8 M | 29.2 M | |
| Non Operating Income Net Other | 786.6 K | 936.5 K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Rigel Pharmaceuticals Correlation against competitors. For more information on how to buy Rigel Stock please use our How to buy in Rigel Stock guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rigel Pharmaceuticals. Anticipated expansion of Rigel directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Rigel Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 1.086 | Earnings Share 6.19 | Revenue Per Share | Quarterly Revenue Growth 0.256 | Return On Assets |
Investors evaluate Rigel Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Rigel Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Rigel Pharmaceuticals' market price to deviate significantly from intrinsic value.
It's important to distinguish between Rigel Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Rigel Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Rigel Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.